Cara Therapeutics Inc (NASDAQ:CARA)
| 28.55 Delayed Data As of 3:59pm ET |  +1.10 / +4.01%Today’s Change | 12.30 Today|||52-Week Range 29.65 | +88.70% Year-to-Date |
Latest CARA News | Press Releases
| Cara (CARA) Surges 14%: Is This an Indication of Further Gains? Apr 07 / Zacks.com - Paid Partner Content | Why Cara Therapeutics Stock Is Soaring Higher Today Apr 06 / MotleyFool.com - Paid Partner Content |
| Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options Apr 07 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 27.45 |
| Today’s open | 27.90 |
| Day’s range | 27.21 - 28.63 |
| Volume | 44,302 |
| Average volume (3 months) | 756,373 |
| Market cap | $1.5B |
Data as of 3:59pm ET, 04/14/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -1,165.08% |
| Earnings growth (next 5 years) | -66.83% |
| Revenue growth (last year) | +579.28% |
| P/E ratio | 158.6 |
| Price/Sales | 5.37 |
| Price/Book | 5.85 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALECAlector Inc | +0.04 | +0.23% |
| REPLReplimune Group Inc | +0.35 | +1.16% |
| TBIOTranslate Bio Inc | +1.24 | +7.13% |
| SAVACassava Sciences Inc | -0.38 | -1.05% |
Data as of 4:00pm ET, 04/14/2021
Financials
| Next reporting date | May 6, 2021 |
| EPS forecast (this quarter) | -$0.58 |
| Annual revenue (last year) | $135.1M |
| Annual profit (last year) | $8.4M |
| Net profit margin | 6.23% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Stamford, Connecticut |
Forecasts
